Orchard Therapeutics plc (NASDAQ:ORTX – Get Rating) – Analysts at Cantor Fitzgerald reduced their FY2022 EPS estimates for shares of Orchard Therapeutics in a research note issued to investors on Wednesday, January 18th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will post earnings of ($1.27) per share for the year, down from their prior forecast of ($1.24). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Orchard Therapeutics’ current full-year earnings is ($1.30) per share. Cantor Fitzgerald also issued estimates for Orchard Therapeutics’ FY2023 earnings at ($0.62) EPS.
Orchard Therapeutics (NASDAQ:ORTX – Get Rating) last posted its quarterly earnings data on Monday, November 14th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.14). Orchard Therapeutics had a negative return on equity of 109.29% and a negative net margin of 1,109.00%. The company had revenue of $5.78 million for the quarter, compared to the consensus estimate of $4.12 million.
Orchard Therapeutics Stock Performance
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in ORTX. Renaissance Technologies LLC increased its holdings in shares of Orchard Therapeutics by 144.0% during the 2nd quarter. Renaissance Technologies LLC now owns 1,986,288 shares of the company’s stock worth $1,160,000 after purchasing an additional 1,172,263 shares during the period. Strategic Wealth Advisors Group LLC bought a new stake in Orchard Therapeutics in the third quarter valued at about $258,000. Millennium Management LLC bought a new stake in Orchard Therapeutics in the second quarter valued at about $106,000. BlackRock Inc. increased its stake in Orchard Therapeutics by 19.9% in the first quarter. BlackRock Inc. now owns 749,990 shares of the company’s stock valued at $534,000 after acquiring an additional 124,478 shares during the period. Finally, Federated Hermes Inc. increased its stake in Orchard Therapeutics by 1.1% in the third quarter. Federated Hermes Inc. now owns 8,401,687 shares of the company’s stock valued at $4,201,000 after acquiring an additional 91,828 shares during the period. Institutional investors own 44.08% of the company’s stock.
Orchard Therapeutics Company Profile
Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies.
- Get a free copy of the StockNews.com research report on Orchard Therapeutics (ORTX)
- Is Virgin Galactic Stock Preparing for Lift-Off?
- Chevron is Likely to Increase its Dividend Before Earnings
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.